Condition: Acute Myeloid Leukemia · Sponsor: National Cancer Institute (NCI)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | Recruiting |
| University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley, California, United States | Suspended |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| UCSF Medical Center-Parnassus | San Francisco, California, United States | Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Memorial Hospital West | Pembroke Pines, Florida, United States | Recruiting |
| Phoebe Putney Memorial Hospital | Albany, Georgia, United States | Recruiting |
| Saint Alphonsus Cancer Care Center-Boise | Boise, Idaho, United States | Recruiting |
| Saint Luke's Cancer Institute - Boise | Boise, Idaho, United States | Recruiting |
+ 166 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05554393